Companies › Getz Pharma
1 active drug program in 3 registered trials: 1 Phase 4, 1 Phase 2, 1 Phase 1; Cardiovascular, Gastroenterology, Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ertugliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 4 | Liver Fat; Heart Failure; Ketones, Metabolism | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05644717 | Ertugliflozin | Phase 4 | Liver Fat | Gastroenterology | Nov 2025 |
| NCT04438213 | Ertugliflozin | Phase 2 | Heart Failure | Cardiovascular | Dec 2025 |
| NCT05662865 | Ertugliflozin | Phase 1 | Ketones, Metabolism | Other | Dec 2026 |
THPharm Boryung Pharmaceutical AstraZeneca Lexicon Pharmaceuticals Boehringer Ingelheim Dong-A ST Hangzhou Zhongmei Huadong Pharmaceutical JW Pharmaceutical
Dr. F. Köhler Chemie Albireo, an Ipsen Company RHEACELL GmbH & Co. KG Tenax Therapeutics Livzon Pharmaceutical Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.